Actively Recruiting
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Led by Jian Chen · Updated on 2025-06-13
48
Participants Needed
1
Research Sites
309 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To observe the efficacy of carbon ion radiotherapy combined with chemotherapy in the treatment of inoperable locally advanced or advanced (all visible lesions can be included in the radiation target area in this treatment) primary thymic epithelial tumor who have no thorax radiotherapy histroy. The patients will receive 72GyE/18fractions of carbon ion radiotherapy. Combined with platinum-containing schemes (including etoposide combined with cisplatin or carboplatin or loplatin or nedaplatin, paclitaxel combined with cisplatin or carboplatin or loplatin or nedaplatin, etc.); Docetaxel combined with cisplatin or carboplatin or loplatin or nedaplatin) for at least 4 cycles. Progression-free survival, local control rate, overall survival and toxicity were calculated.
CONDITIONS
Official Title
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with inoperable locally advanced or advanced thymic epithelial tumor confirmed by pathology
- No previous thoracic radiation therapy
- All visible lesions can be included in the radiation target area during treatment
- Age between 18 and 70 years
- Signed informed consent
- ECOG general status score of 0 to 2
- Expected survival of at least 6 months
- Adequate organ function including blood counts, lung function (FEV1 > 25%, DLCO > 25%), cardiac function without serious heart or vascular diseases, liver function with bilirubin and liver enzymes within specified limits, and kidney function with serum creatinine and urinary protein within limits
You will not qualify if you...
- Presence of other uncontrolled malignant tumors
- Large amounts of pleural or pericardial effusion
- Inability to meet radiotherapy dose coverage and normal tissue dose constraints
- History of chest radiation therapy or radioactive particle implantation
- Presence of cardiac pacemakers or metal implants that interfere with radiation
- Pregnancy or breastfeeding
- HIV positive or active viral infections requiring antiviral therapy but unable to receive it
- Active syphilis
- History of mental illness that may prevent treatment completion
- Serious comorbidities interfering with radiotherapy such as acute infections, recent severe heart conditions, severe respiratory disease exacerbations, impaired immune function, diseases with high radiation sensitivity, or other physician-determined factors preventing participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Proton and Heavy Ion Center
Shanghai, Shanghai Municipality, China, 201513
Actively Recruiting
Research Team
J
Jing Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here